House Foods Group (2810) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
13 Jul, 2026Executive summary
Net sales for the nine months ended December 31, 2024, rose 6.1% year-over-year to ¥239,357 million, driven by growth in core food segments and international expansion.
Operating profit increased 6.2% year-over-year to ¥17,699 million, with notable gains in the Spice/Seasoning/Processed Food segment.
Profit attributable to owners of parent declined 25.6% year-over-year to ¥12,172 million, mainly due to the absence of a prior-year gain on retirement benefit plan revision.
Financial highlights
Gross profit rose to ¥88,582 million from ¥82,706 million year-over-year.
Ordinary profit increased 4.5% year-over-year to ¥18,395 million.
EPS (basic) was ¥128.14, down from ¥167.74 in the prior year.
Comprehensive income dropped 59.0% year-over-year to ¥11,723 million.
Equity ratio remained strong at 67.5% as of December 31, 2024.
Outlook and guidance
Full-year forecast for FY2024 remains unchanged: net sales ¥320,000 million (+6.8%), operating profit ¥21,000 million (+7.9%), profit attributable to owners of parent ¥13,300 million (-24.3%).
Dividend forecast for FY2024 is ¥48.00 per share.
Latest events from House Foods Group
- Sales and operating profit rose, but net profit fell due to last year's one-time gain.2810
Q1 202513 Jul 2026 - Sales and operating profit rose, but net profit fell on one-off factors; record profit targeted.2810
Q2 202513 Jul 2026 - Sales and operating profit increased, but net profit dropped sharply on one-time items.2810
Q4 202513 Jul 2026 - Profits fell on higher costs and weak demand, but stable dividends and a 2H recovery are forecast.2810
Q2 202613 Jul 2026 - Sales rose modestly, but profits fell sharply on higher costs; outlook and dividend unchanged.2810
Q1 202613 Jul 2026 - Sales grew modestly, but profits declined due to rising costs and inflationary pressures.2810
Q3 202613 Jul 2026 - Profits fell on higher costs and U.S. impairments, but FY2027 profit set to rebound on asset sales.2810
Q4 202613 Jul 2026